Champions Oncolog CSBR

$4.82 +0.10 (2.12%)

Valuation

Market cap
65,698,000
Revenue TTM
$59,430,000
Net income TTM
$-1,180,000
PE ratio
0.00
Forward PE
—
Profit margin
-1.99%
Debt to equity
0.00

Trading

Volume
15,125
Avg volume
10,816
Day's range
$4.80 – $4.98
Shares out
13,919,000
Stochastic %K
17%
Beta
0.44
Analysts
Strong Buy
Price target
$12.00

Price

Company profile

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research service...

Show more

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
201 808 8400
Website
https://www.championsoncology.com
Address
One University Plaza, Suite 307, Hackensack, United States

Latest news

No headlines yet.